{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-25-000021","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.389336+00:00","generated_at":"2026-05-21T23:53:00.388455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027","bullets":["Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.","Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.","Guidance: cash sufficient to fund operations into Q4 2027.","Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.","Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-25-000021","json":"https://secwatch.observer/filing/0001701541-25-000021.json","markdown":"https://secwatch.observer/filing/0001701541-25-000021.md","text":"https://secwatch.observer/filing/0001701541-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/0001701541-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154125000021/bdtx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:53:00.388455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}